UTI MF- Fund Review write-up for the month activity

Chandigarh, January 15, 2025: In contrast to the biological life cycle, companies do go through periods of growth and saturation. Mid-cap companies capture a period in the typical business life cycle, wherein companies have successfully navigated the phase inherent to small companies, such as raising initial capital, and managing early growth challenges; however, these companies are likely to sustain leadership, operate with significant moat, and they are not so large that their ability to grow fast is disparaging. Therefore, mid-cap companies can offer a sweet spot between fast-growing small businesses and well-established large companies.

Mid-cap stocks fall between large-cap and small-cap stocks and are typically determined based on the market capitalization of the companies. As defined by SEBI, 101st to 250th companies by full market capitalization are mid-cap stocks. A mid-cap fund predominantly invests a minimum of 65% of the fund’s corpus in equity & equity-related instruments of mid-cap companies.

The Funds investing in mid-cap companies provide investors an opportunity to benefit from the growth stories of medium-sized businesses. However, investors should take cognizance of their inherent risks, as both the risk and reward potential of mid-cap funds are relatively higher than that of well-diversified growth funds.

UTI Mid Cap Fund is an open-ended equity scheme investing predominantly in mid-cap companies. The Fund’s strategy focuses on investing in companies with scalable business models and a long growth runway. The Fund is also open to investing in good companies whose businesses are going through a transitory phase of weakness or undergoing a transformation. The Fund pursues a pure bottom-up stock selection approach to pick businesses with healthy financials and potential for the sustenance of margins over some time. The Fund also has a well-diversified portfolio with about 87 stocks covering various sectors and industries.

The Fund came into existence on April 7, 2004, and has an AUM of over Rs. 11,990 crores as of December 31, 2024. The Fund is a true-to-label product and therefore, would prefer to have an allocation in mid cap and small cap companies in the range of 85-90% in the portfolio at all points in time. The Fund has about 69% invested into mid cap companies, 24% into small cap companies and the remaining in large cap companies as on December 31, 2024. The scheme’s top holdings consist of Coforge Ltd., Persistent Systems Ltd., PB Fintech Ltd., Polycab India Ltd., Phoenix Mills Ltd., Ajanta Pharma Ltd., Alkem Laboratories Ltd., Voltas Ltd., Tube Investments of India Ltd., and Solar Industries India Ltd., which account for about 21% of the portfolio’s holdings.

The Fund with its diversified exposure aims to strike a balance between risk and reward by following a patient approach towards companies in the portfolio and with the right mix of companies with a strong Return on Capital Employed (RoCE) and Cash flow profile. This is likely to aid in mitigating sharp return divergence and volatility of the portfolio.

UTI’s rich experience in research and fund management, coupled with the coverage of large cross section of companies in the mid and small cap universe will help the Fund in picking quality stocks and also avoid the poor ones.

UTI Mid Cap Fund is suitable for investors looking for an investment in a portfolio predominantly investing in mid cap companies and willing to supplement their core equity portfolio with its underlying growth potential.

Leave a Reply

Your email address will not be published. Required fields are marked *